BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Sun Pharmaceutical Industries Ltd. delivered a lower-than-expected Q4 FY22 due to moderation in the Rest of World/emerging markets/active pharma ingredient segment and higher opex.
The specialty portfolio continues to progress well, with its contribution to sales rising to 13% in FY22 from 7% in FY18.
We tweak our FY23/FY24 earnings per share estimate by down 4%/down 3%, factoring in:
higher research and development spend on clinical trials,
high opex-related to promotional activities and supply chain management, and
weakness in API offtake to some extent.
We remain positive on Sun Pharma on the back of:
a strong outperformance in the branded generics segments of domestic formulation/RoW/EMs,
scale-up of the specialty portfolio, and
niche launches in the U.S. generics segment.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
